When the comparative analysis with healthy individuals was performed after stratification of the MS subjects, according to the immunomodulatory treatment they underwent (Figure 1B), we found a significant increase in the intracellular content of SOD-1 in T cells only in MS-RR subjects not treated with fingolimod (p < 0.005). This evidence concerns the gene SOD1 and myeloid sarcoma.